Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?

Weight gain and increase in B‐Type Natriuretic Peptide have been advocated as means of aiding diagnosis of heart failure. However, there are few data to support the use of these criteria in diagnosing clinical deterioration in patients with established disease.

[1]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[2]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[3]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[4]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[5]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[6]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[7]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[8]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[9]  J. Cahill,et al.  Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high‐risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin‐converting enzyme inhibitor dose at discharge , 2001, European journal of heart failure.

[10]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[11]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[12]  A. Wu,et al.  Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. , 2003, The American journal of cardiology.

[13]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[14]  J. Cahill,et al.  Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. , 2002, Journal of cardiac failure.

[15]  J. Marving,et al.  Symptoms and signs of heart failure in patients with myocardial infarction: reproducibility and relationship to chest X-ray, radionuclide ventriculography and right heart catheterization. , 1989, European heart journal.

[16]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[17]  T. McDonagh,et al.  NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. , 2003, European journal of heart failure.

[18]  A. Richards,et al.  Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. , 1997, American journal of physiology. Heart and circulatory physiology.

[19]  Andrew K. Smith,et al.  Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure , 2004, European journal of heart failure.